Blood level of CD45+platelets and development of restenosis after drug-eluting stent implantation in patients with stable coronary artery disease

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F62157124%3A16370%2F16%3A43874479" target="_blank" >RIV/62157124:16370/16:43874479 - isvavai.cz</a>

Alternative codes found

RIV/00216224:14110/16:00098628

Result on the web

<a href="http://dx.doi.org/10.1007/s00508-016-1074-x" target="_blank" >http://dx.doi.org/10.1007/s00508-016-1074-x</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s00508-016-1074-x" target="_blank" >10.1007/s00508-016-1074-x</a>

Result language

angličtina

Original language name

Blood level of CD45+platelets and development of restenosis after drug-eluting stent implantation in patients with stable coronary artery disease

Original language description

The aim of this study was to assess CD45-positive platelets (CD45+ platelets) involvement in restenosis development after drug-eluting stent (DES) implantation in patients with stable coronary artery disease (CAD). The study comprised 126 male and female patients with stable angina pectoris, who underwent elective coronary stenting with DES and follow-up angiography within 6-12 months. The patients were assigned to the group with restenosis (n = 53) or group without restenosis (n = 73) according to the follow-up angiograms. In both groups we compared the level in blood of CD45+ platelets, the clinical, laboratory and angiographic variables, which may affect the development of restenosis. We have also constructed a logit regression model for prognosis of restenosis occurrence after DES implantation. The blood count of CD45+ platelets was higher in patients with restenosis than in patients without: 0.82 % (0.58; 1.12) vs. 0.34 % (0.20; 0.68), p < 0.001, data are expressed as median (lower quartile; upper quartile). By binary comparisons of more than 35 different clinical, laboratory and angiographic variables we identified 8 significant risk factors for the development of stent restenosis after DES. In order to define the risk of the development of restenosis, we have built a logit regression model. The resulting logit regression equation included the level of CD45+ platelets, the neutrophil to lymphocyte ratio (NLR), small diameter arteries stenting and the number of simultaneously implanted stents in one patient. Receiver operating characteristic (ROC) curve analysis has demonstrated the high prognostic value of the resulting logit regression equation with an area under the curve (AUC) of 0.91 % (p < 0.001). The acquired data indicate the presence of a close relationship between circulating CD45+ platelets and restenosis development after DES implantation in patients with stable CAD

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FR - Pharmacology and apothecary chemistry

OECD FORD branch

—

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2016

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Wiener Klinische Wochenschrift

ISSN

0043-5325

e-ISSN

—

Volume of the periodical

128

Issue of the periodical within the volume

23-24

Country of publishing house

AT - AUSTRIA

Number of pages

8

Pages from-to

898-905

UT code for WoS article

000390030000008

EID of the result in the Scopus database

—